46 research outputs found
Le déficit en glucose-6 phosphate déshydrogénase : protection contre le paludisme et risque d'accidents hémolytiques
L’hémoglobine, des micro-organismes à l’homme : un motif structural unique, des fonctions multiples
Mutations in the paralogous human α-globin genes yielding identical hemoglobin variants
The human α-globin genes are paralogues, sharing a high degree of DNA sequence similarity and producing an identical α-globin chain. Over half of the α-globin structural variants reported to date are only characterized at the amino acid level. It is likely that a fraction of these variants, with phenotypes differing from one observation to another, may be due to the same mutation but on a different α-globin gene. There have been very few previous examples of hemoglobin variants that can be found at both HBA1 and HBA2 genes. Here, we report the results of a systematic multicenter study in a large multiethnic population to identify such variants and to analyze their differences from a functional and evolutionary perspective. We identified 14 different Hb variants resulting from identical mutations on either one of the two human α-globin paralogue genes. We also showed that the average percentage of hemoglobin variants due to a HBA2 gene mutation (α2) is higher than the percentage of hemoglobin variants due to the same HBA1 gene mutation (α1) and that the α2/α1 ratio varied between variants. These α-globin chain variants have most likely occurred via recurrent mutations, gene conversion events, or both. Based on these data, we propose a nomenclature for hemoglobin variants that fall into this category
Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations
HbVar (http://globin.bx.psu.edu/hbvar) is a widely-used locus-specific database (LSDB) launched 20 years ago by a multi-center academic effort to provide timely information on the numerous genomic variants leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies. Here, we report several advances for the database. We made clinically relevant updates of HbVar, implemented as additional querying options in the HbVar query page, allowing the user to explore the clinical phenotype of compound heterozygous patients. We also made significant improvements to the HbVar front page, making comparative data querying, analysis and output more user-friendly. We continued to expand and enrich the regular data content, involving 1820 variants, 230 of which are new entries. We also increased the querying potential and expanded the usefulness of HbVar database in the clinical setting. These several additions, expansions and updates should improve the utility of HbVar both for the globin research community and in a clinical setting
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach
We developed a series of interrelated locus-specific databases to store all published and unpublished genetic variation related to hemoglobinopathies and thalassemia and implemented microattribution to encourage submission of unpublished observations of genetic variation to these public repositories. A total of 1,941 unique genetic variants in 37 genes, encoding globins and other erythroid proteins, are currently documented in these databases, with reciprocal attribution of microcitations to data contributors. Our project provides the first example of implementing microattribution to incentivise submission of all known genetic variation in a defined system. It has demonstrably increased the reporting of human variants, leading to a comprehensive online resource for systematically describing human genetic variation in the globin genes and other genes contributing to hemoglobinopathies and thalassemias. The principles established here will serve as a model for other systems and for the analysis of other common and/or complex human genetic diseases
Hétérérogénéité génétique de la polyglobulie
La polyglobulie (PG) a un arrière plan clinique et physiopathologique varié, et dont la connaissance a beaucoup évolué depuis 5 ans. Elle a pour caractéristique nécessaire et commune une augmentation du volume globulaire total qui peut résulter de mécanismes moléculaires différents. L'érythrocytose est une forme de la PG ou seule la lignée érythroïde semble être augmentée. Dans ce contexte, nous nous sommes intéressés à la mutation JAK2 (Val617Phe) et aux gènes EPOR, VHL, PHD2 chez des patients présentant une érythrocytose d'origine inconnue (98 familles). Nous avons trouvé 3 nouvelles mutations délétionnelles et d'autres mutations faux-sens et silencieuses sur EPOR. Les cellules FDCP-1 et 32D transfectées, qui expriment les récepteurs tronqués ont montré une hypersensibilité à l'Epo à concentration basse. Les analyses Epo-dose-réponse pour une mutation faux-sens étaient semblables à celles du type sauvage. La mutation JAK2(Val617Phe) était présente avec une faible fréquence dans la série de patients étudiés. La recherche des mutations dans le gène PHD2 nous a permis de trouver 3 nouvelles mutations frame-shift et non-sens, les seules connues à ce jour: Elles entraînent la perte d'une partie ou de l ensemble du site catalytique de PHD2 dans l hypothèse où elles seraient synthétisées. Ainsi, ces mutations et les deux autres mutations faux-sens décrites démontrent l'importance de PHD2 dans la régulation de la voie de HIF-a, et qu'une perturbation de cette régulation pourrait conduire à une PG. La majorité des patients reste sans défaut moléculaire identifié, et des recherches complémentaires sont nécessaires. Nous avons également étudié deux Hbs augmentant l'affinité pour l'oxygène: les Hbs Nantes et La Coruña. Enfin, nous avons cherché des mutations dans les 3 exons de DPGM chez 4 patients avec un taux de 2,3-DPG bas. Une seule mutation a été trouvée dans la région 5, dans l'exon 1 non traduit, elle nécessite des études complémentaires.Polycythemia has a varied clinical and physiopathological background, of which our knowledge has greatly evaluated since 5 years. It is characterised by augmentation of the red cell mass which can be resulted from different molecular mechanisms. Erythrocytosis is a form of polycythemia where only the erythrocytes are augmented. In this context, we looked for the mutation JAK2 (Val617Phe), and other mutations in the genes of EPOR, VHL, PHD2 in a series of patients with erythrocytosis of unknown origin (98 families). We found 3 new frame-shift mutations and other missense and silent mutations in the EPOR. Transfected FDCP-1 and 32D cell lines expressing a truncated EpoR showed increased sensitivity at low concentration of Epo. However, in the case of a missense EPOR mutation, the Epo-dose response assays were similar to that of the wild type. The mutation JAK2 (Val617Phe) was found at a low frequency in the studied patients. Looking for mutations in the PHD2 gene allowed us to find 3 new frame-shift and nonsense mutations, the only reported to date. The encoded PHD2, if synthesized, would lose its active site or a part of it. These mutations with the other two missense mutations reported provide the evidence of the importance of PHD2 in the regulation of HIF-a pathway, and that disturbing the oxygen-sensing pathway might be a cause of polycythemia. The molecular basis of polycythemia in the majority of patients is still to be identified, and complementary studies are necessary. We studied then two examples of Hbs with a high oxygen affinity: Hb Nantes et La Coruña. Finally, we looked for mutations in the 3 exons of DPGM in a series of 4 patients. One mutation in exon 1 in the 5region was found, and needs further studies.PARIS-EST-Université (770839901) / SudocPARIS12-Bib. électronique (940280011) / SudocSudocFranceF
HB belliard [α56(e5)LYS→ASN] a new fast-moving α chain variant found in a subject of Spanish origin
SCOPUS: ar.jinfo:eu-repo/semantics/publishe